DO方案与NO方案治疗老年晚期非小细胞肺癌疗效观察

Effects of Docetaxel Plus Oxaliplatin Regimen Vs.Vinorelbine Plus Oxaliplatin Regimen on Senile Advanced Non-Small Cell Lung Cancer

目的评价多烯紫杉醇(DOC)加奥沙利铂(OXA)与长春瑞滨(NVB)加奥沙利铂方案治疗老年晚期非小细胞肺癌临床疗效和安全性。方法经病理组织学或细胞学确诊为晚期非小细胞肺癌的老年患者45例(年龄>65岁)为研究对象,以1∶1比例随机分为多烯紫杉醇联合奥沙利铂(DO)组24例与长春瑞滨联合奥沙利铂(NO)组21例,DO组奥沙利铂130 mg/m2,静脉滴注2 h,第1天,多烯紫杉醇75 mg/m2,静脉滴注3 h,第2天;NO组为长春瑞滨25 mg/m2静脉滴注,第1,8天,奥沙利铂用法同DO组。每3周重复一次,均行3周期治疗,按照RECIST标准评价疗效和不良反应。结果 DO组24例,完全缓解(CR)4例,部分缓解9例(PR),稳定6(SD)例,总有效率为54.17%(13/24);NO组21例,完全缓解3例,部分缓解8例,稳定6例,总有效率52.38%(11/21)。DO组和NO组两组患者临床疗效差异无统计学意义(P>0.05)。DO组恶心、呕吐反应,血红蛋白下降和神经毒性均较NO组低。结论 DO方案与NO方案治疗老年晚期非小细胞肺癌的疗效相似,但DO方案较NO方案不良反应轻,老年患者更容易耐受,是老年晚期非小细胞肺癌较理想的化疗方法。

Objective To compare the effect and safety of Docetaxel ＋ Oxaliplatin regimen vs.Vinorelbine ＋ Oxaliplatin regimen in the treatment of senile advanced non-small cell lung cancer（NSCLC）.Methods Total of 45 elderly patients（age65） with advanced NSCLC diagnosed by pathology examination were randomly divided into Docetaxel＋Oxaliplatin（DO） regimen gorup and Vinorelbine＋Oxaliplatin（NO） regimen group in a rate of 1∶1,24 patients in DO group and 21 patients in NO group.The DO group received Oxaliplatin 130 mg/m2,iv drip,2 hours,d1,and Docetaxel 75 mg/m2,iv drip,3 hours,d2;while the NO group received Vinorelbine 25 mg/m2,iv drip,1/2 hours,d1,8,and Oxaliplatin used as DO group.Every patient was repeated every 3 weeks and was given 3 cycles.The efficacy and toxicity was then evaluated.Results Twenty four cases could be evaluated in the DO group and 21 cases in the NO group.In DO group,the overall response rate was 54.17%（13/24） and 52.38% in NO group（11/21）.There was no statistically difference between the two groups regarding clinical result.The nausea and vomiting reaction and the decrease of hemoglobin and neurotoxicity were more in NO group.Conclusion The efficacy is similar for 2 regimens in the treatment of senile advanced NSCLC.DO project is relatively well tolerated and better chemotherapy method.